The Non-Malignant Channel is supported with funding from Agios (Gold).
VJHemOnc is an independent medical education platform. Supporters, including channel supporters, have no influence over the production of content. The levels of sponsorship listed are reflective of the amount of funding given to support the channel.
EHA 2026 | 3-year COMMODORE-1 data support long-term crovalimab in PNH
Yasutaka Ueda, MD, PhD, Osaka University, Suita, Japan, discusses 3-year data from the COMMODORE-1 study (NCT04432584) evaluating crovalimab in patients with paroxysmal nocturnal hemoglobinuria (PNH) who switched from ravulizumab. He highlights sustained efficacy, a favorable long-term safety profile, and the potential of subcutaneous crovalimab as a convenient long-term treatment option. This interview took place at the 31st Congress of the European Hematology Association (EHA) in Stockholm, Sweden.
These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.
